Emily L. Heil, PharmD, MS, FIDP, BCIDP, AAHIVP

In the sixth and final episode, the clinicians unpack the most debated change in the guidance, the move to cefiderocol monotherapy as the preferred option for invasive S maltophilia infections, and invite community feedback.

In part 5 of the series, the clinicians explain the shift toward sulbactam-durlobactam for invasive carbapenem-resistant Acinetobacter baumannii infections and how hospitals with low CRAB volume can still plan for access.

In the fourth episode of a 6-part series, the clinicians compare agents for DTR P aeruginosa and explain why local antibiogram data should guide empiric choices.

In the third episode, the clinicians compare aztreonam-avibactam with cefiderocol for NDM-producing Enterobacterales, weigh formulary needs against local epidemiology, and discuss stewardship planning for emerging agents.

In part 2 of a 6-part series, the clinicians explain why the 2026 guidance now organizes CRE treatment by carbapenemase type and why meropenem-vaborbactam earned a slight edge for KPC producers.

This is the first in a series of discussions between medical peers on the 2026 IDSA guidance for antimicrobial-resistant gram-negative infections, beginning with current clinical challenges and new options for ESBL- and AmpC-producing organisms.